Welcome to our dedicated page for Entrada Therapeutics SEC filings (Ticker: TRDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Entrada Therapeutics, Inc. (Nasdaq: TRDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Entrada is a clinical-stage biopharmaceutical company developing RNA- and protein-based therapeutics using its Endosomal Escape Vehicle (EEV™) technology for neuromuscular, ocular and other diseases.
For TRDA, key filings include periodic reports and current reports on Form 8-K. Recent Form 8-K filings furnished by Entrada cover quarterly financial results and corporate updates, such as results for the quarters ended June 30, 2025 and September 30, 2025. These filings confirm that Entrada’s common stock is registered on The Nasdaq Global Market under the symbol TRDA and identify the company as an emerging growth company.
Through this page, users can review how Entrada reports on its financial condition, collaboration revenue, research and development expenses, and other operating metrics in documents that are incorporated by reference into its SEC record. While the detailed content of annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy statements is not reproduced here, this filings hub is the starting point for locating those documents on EDGAR.
Stock Titan enhances access to Entrada’s SEC filings by organizing them chronologically and highlighting document types that matter to investors, such as Forms 8-K, 10-K, 10-Q and, when applicable, insider transaction reports on Form 4. AI-driven tools can help summarize lengthy filings and clarify technical language, allowing readers to more quickly understand how Entrada describes its EEV platform, clinical programs and financial results in its official regulatory disclosures.
Entrada Therapeutics President & COO Nathan J. Dowden reported open-market sales of a total of 15,010 shares of common stock. He sold 3,116 shares on March 9, 2026 at a weighted average price of $13.024 per share and 11,894 shares on March 10, 2026 at a weighted average price of $13.0476 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 7, 2025. After the most recent sale, Dowden directly holds 198,588 shares of Entrada Therapeutics common stock.
Entrada Therapeutics, Inc. Chief Financial Officer Kory James Wentworth reported open-market sales of company common stock. He sold 5,089 shares on March 9, 2026 at a weighted average price of $13.0011 per share and 11,388 shares on March 10, 2026 at a weighted average price of $13.0151 per share. These transactions, totaling 16,477 shares, were executed pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2025. After the most recent sale, he directly holds 121,510 shares of Entrada common stock.
Kory Wentworth reported planned sales of Common Stock under a 10b5-1 plan. The filing lists three trades: 03/02/2026 sale of 2,939 shares for $34,262.57, 03/03/2026 sale of 5,712 shares for $67,152.56, and 03/04/2026 sale of 7,988 shares for $97,892.14. The broker listed is Morgan Stanley Smith Barney LLC. The filing also records securities listed as previously exercised stock options (9,395 shares, 06/29/2023) and restricted stock units (7,082 shares, 09/01/2025).
Nathan Dowden reported two sales of Common stock: 7,223 shares on 03/02/2026 for $84,205.01 and 14,038 shares on 03/03/2026 for $165,036.34. The filing also lists 15,010 Restricted Stock Units dated 03/01/2024 and a securities line showing 38,284,313 (03/09/2026).
Entrada Therapeutics Chief Financial Officer Kory James Wentworth sold 7,988 shares of common stock in an open-market transaction. The sale occurred on March 4, 2026 at a weighted average price of $12.2549 per share, with individual trade prices ranging from $11.80 to $12.57.
The transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the executive on March 6, 2025. Following this sale, Wentworth directly holds 137,987 shares of Entrada Therapeutics common stock.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 relating to TRDA securities, showing 7,988 restricted stock units listed to be sold by the broker/issuer role on 03/01/2026. The filing also reports recent dispositions by Kory Wentworth of 5,712 and 2,939 common shares on 03/03/2026 and 03/02/2026, respectively, with reported proceeds of $67,152.56 and $34,262.57.
Entrada Therapeutics CEO Dipal Doshi reported new equity awards and automatic tax-related share sales. On March 1, 2026, Doshi received 139,400 restricted stock units under the 2021 Stock Option and Incentive Plan and a stock option covering 208,000 shares of common stock, both granted at $0.00 per share.
The RSUs vest in four 25% installments each March 1 from 2027 through 2030, while 25% of the option vests on March 1, 2027 and the rest monthly through March 1, 2030. On March 2 and 3, 2026, a total of 29,050 shares of common stock were automatically sold by the company under a mandatory sell-to-cover provision to satisfy minimum tax withholding, at weighted average prices of $11.6579 and $11.7564 per share.
Following these transactions, Doshi directly owned 526,014 shares of Entrada Therapeutics common stock.
Entrada Therapeutics Chief Financial Officer Kory James Wentworth reported equity compensation grants and related tax-withholding share dispositions. On March 1, 2026, he received 66,600 stock options and 44,600 restricted stock units under the 2021 Stock Option and Incentive Plan, both vesting in stages through March 1, 2030.
The filing also shows mandatory sell-to-cover transactions where the company automatically sold 5,712 shares at a weighted average price of $11.7564 on March 3, 2026 and 2,939 shares at $11.6579 on March 2, 2026 to cover minimum statutory tax withholding obligations, not discretionary trades by Wentworth. After these transactions, he directly owned 145,975 common shares and 66,600 options.
Entrada Therapeutics President & COO Nathan J. Dowden reported equity compensation grants and related tax-withholding share dispositions. On March 1, 2026, he received 55,800 shares of common stock as restricted stock units and a stock option for 83,200 shares, both granted at $0.00 per share.
The RSUs vest in four equal 25% installments each March 1 from 2027 through 2030, while the option vests 25% on March 1, 2027 and the remaining 75% in 36 monthly installments through March 1, 2030. On March 2 and March 3, 2026, a total of 21,261 shares of common stock were automatically disposed of at weighted average prices of $11.6579 and $11.7564 to satisfy minimum statutory tax withholding obligations under a mandatory sell-to-cover provision, and did not represent discretionary trades. After these transactions, Dowden directly held 213,598 shares of common stock and 83,200 option shares.
Entrada Therapeutics, Inc. reported that President of Research & Development Sethuraman Natarajan received new equity awards and had shares disposed to cover tax obligations. On March 1, 2026, he was granted 55,800 restricted stock units (RSUs), each representing one share of common stock, scheduled to vest 25% each on March 1, 2027, March 1, 2028, March 1, 2029, and March 1, 2030, contingent on continued service. He also received a stock option for 83,200 shares of common stock, with 25% vesting on March 1, 2027 and the remaining 75% vesting in 36 equal monthly installments through March 1, 2030. To satisfy minimum statutory tax withholding obligations, the company automatically sold shares on his behalf: 3,898 shares of common stock on March 2, 2026 at a weighted average price of $11.6579 (across trades from $11.17 to $11.91) and 7,577 shares on March 3, 2026 at a weighted average price of $11.7564 (across trades from $11.22 to $12.095). After these transactions, he directly owned 242,224 shares of Entrada’s common stock.